SOPHiA GENETICS and AstraZeneca have signed a multi-year agreement to develop and deploy decentralized companion diagnostics for solid tumors and blood cancers, aiming to expand local lab access to precision oncology testing.
Labcorp has announced the upcoming launch of the Marker by Labcorp Genetic Health Panel, which will analyze 163 genes linked to over 100 medically actionable conditions, with results supported by licensed genetic counselors.
Myriad Genetics has launched the FirstGene Multiple Prenatal Screen, a test that combines four prenatal genetic screens from a single blood draw as early as eight weeks gestation, according to the company.
Bio-Rad has launched Vericheck ddPCR kits for quality control in cell and gene therapy manufacturing, offering validated workflows for mycoplasma detection, capsid analysis, and residual DNA quantification.
Read More
The test utilizes genomic sequencing and AI to identify biological signals associated with early-stage disease.
Read More
The transaction includes subsidiaries in the United States, Sweden, and Australia to expand transplantation diagnostic offerings.
Read More
Research suggests new sequencing technologies can help labs move from tissue-level averages to cell-specific testing for precision exercise medicine.
Read More
HerAnova Lifesciences presented validation data for HerResolve, a blood-based endometriosis test, showing 94.4% accuracy and detection of cases missed by imaging.
Read More
Roche has launched AXELIOS 1, a single-molecule sequencing platform that uses sequencing by expansion technology to deliver same-day whole-genome results.
Read More
The agreement combines extraction and PCR technologies to create an end-to-end workflow for DNA and RNA analysis.
Read More
The new technologies address library normalization and amplification accuracy for high-throughput and oncology sequencing.
Read More
The whole-genome sequencing assay is now available for breast, colorectal, and renal cancers following new clinical study results.
Read More
The NCCN has updated its bladder cancer guidelines to include FDA-approved ctDNA-based MRD testing for post-surgical risk assessment and adjuvant immunotherapy decisions in muscle-invasive bladder cancer.
Read More
The point-of-care assay provides results in 15 minutes and received a waiver for use in decentralized settings.
Read More
A study reports that an OpenAI reasoning model improved rare disease diagnostic yield by 4.8% in previously unsolved cases, offering new leads after specialist analysis.
Read More
The Fleming Initiative and Cepheid have launched a 30-month study in England to compare rapid molecular and traditional culture screening for drug-resistant carbapenemase-producing Enterobacterales in hospital settings.
Read More
A study reports that long-read genome sequencing can replace up to 15 separate tests and improve diagnostic yield for rare genetic disorders, according to researchers in the Netherlands.
Read More
The NCCN has updated its guidelines to recommend cerebrospinal fluid-based molecular profiling for inoperable high-grade gliomas and glioblastomas, expanding indications for liquid biopsy in CNS cancer care.
Read More